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Abstract 
Background: Accumulating evidence suggests that the gut microbiota shapes developmental processes within the 
immune system. Early life antibiotic use is one factor which may contribute to immune dysfunction and the recent 
surge in allergies by virtue of its effects on gut microbiota.
Objective and methods: As a first step towards determining whether a relationship exists between perinatal anti-
biotic induced changes in the gut microbiota and the later development of a peanut allergy, we exposed newborn 
mice to either the broad-spectrum antibiotic vancomycin or to a vehicle for 6 weeks and then used a novel murine 
model of peanut allergy.
Results: Early-life treatment with vancomycin resulted in a significant shift in the gut microbiota community char-
acterized by a reduction in the abundance of firmicutes and preponderance of inflammatory proteobacteria. Mice 
with an antibiotic-altered microbiota, showed a localized allergic-like response characterized by ear swelling and 
scratching following intra-dermal peanut antigen challenge. Likewise, circulating IgE levels were increased in anti-
biotic-treated mice, but no evidence of a systemic allergic or anaphylactic-like response was observed. Importantly, 
we utilized the naturally occurring pro-inflammatory cytokine, tumor necrosis factor-α (TNF-α), rather than the more 
commonly used cholera toxin, as an adjuvant together with the peanut antigen.
Conclusion: Our data suggest that early antibiotic exposure promotes a shift in the gut microbiota community that 
may in turn, influence how mice later respond to a TNF-α + antigen challenge. However, further studies verifying 
the capacity of microbiota restoration to protect against allergic responses will be needed to confirm a causal role of 
antibiotic-induced microbiota variations in promoting allergic disease phenotypes.
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Background
Over the past few decades, the prevalence of allergic dis-
eases such as asthma, eczema, rhinitis, and food allergy 
has increased at such an alarming rate that these diseases 
now represent some of the most common chronic child-
hood health conditions in affluent countries [1, 2]. Rising 
food allergy rates represent an especially urgent health 
care concern, as food allergies are often comorbid with 
other forms of allergy, can be life-threatening, and have 
only food avoidance as their primary treatment strat-
egy [3]. The geographical localization and shear speed 
at which food allergy rates have risen in “Westernized” 
countries suggest a possible role for environmental fac-
tors in driving these trends [2]. Recent studies highlight-
ing the importance of the community of commensal and 
symbiotic bacteria inhabiting the gastrointestinal tract, 
known as the gut microbiota, in human health suggest 
that the over-prescription of antibiotics to young chil-
dren may represent one such factor. This practice, in 
combination with other factors related to antimicrobial 
and hygienic vigilance, may be inadvertently altering the 
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establishment, composition, and community structure of 
the gut microbiota of the infant intestinal tract when the 
immune system is still maturing. Resulting states of gut 
microbiota dysbiosis may thus in turn be influencing the 
incidence of allergic conditions at the population level 
[4].
Dysbiosis-induced immunopathology and dysregu-
lation of the infant immune system is a central tenet of 
the “microbiota hypothesis” [5–11], a modern varia-
tion of Strachan’s original 1989 “hygiene hypothesis”. In 
addition to aiding in digestion, nutrient absorption, vita-
min production, and the prevention of colonization by 
pathogenic bacteria [12, 13], the gut microbiota plays 
a central role in immunity and is critical for the proper 
development of tolerance-inducing regulatory T (Treg) 
cells and immunoglobulin-producing B cells [14–18]. In 
light of these findings, epidemiological studies support-
ing the microbiota hypothesis have begun to identify 
links between early life factors that can alter the normal 
gut microbiota, including antibiotic use, and the promo-
tion of later allergy development [19]. Antibiotics such 
as vancomycin are capable of inducing potent and rapid 
alterations to the composition and diversity of the micro-
bial species in the intestinal tract, and trends in antibi-
otic prescription rates parallel those of allergic conditions 
[2, 6]. Antibiotic exposure early in life during the critical 
perinatal microbial colonization period may be of par-
ticular importance, as it appears as though there is a ‘crit-
ical window’ during this period in which the gut biota has 
the greatest potential to exert immunomodulatory effects 
on the host [17].
We experimentally tested the hypothesis that early life 
(perinatal) exposure to the antibiotic vancomycin would 
provoke a shift in the gut microbiota community that 
would in turn be associated with increased sensitivity to 
the development of an allergic response to peanut anti-
gen. Vancomycin has previously been shown to induce 
strong shifts in the gut microbiota linked to asthma 
exacerbation [19] and is often used for difficult to treat 
bacterial infections, such as those caused by Clostrid-
ium difficile, which can result in intestinal inflammation 
and changes in gut microbiota [20]. Vancomycin is also 
often used to treat severe and life-threatening infec-
tions (including osteomyelitis, endocarditis, meningitis) 
caused by organisms such as methicillin-resistant Staph-
ylococcus aureus (MRSA), coagulase negative Staphy-
lococcus, and Enterococcus, as well as infections seeded 
from a central line, dialysis/other shunt, or prosthetic 
heart valve.
Our secondary hypothesis was that the pro-inflamma-
tory cytokine, tumor necrosis factor-α (TNF-α), would 
act as an adjuvant to increase sensitivity to the peanut 
antigen when administered concurrently. While most 
murine allergy models involved the use of cholera toxin 
(CT) as an adjuvant [21, 22], we opted for TNF-α due 
to its lower non-specific toxicity and the fact that as an 
endogenous cytokine, with well-known inflammatory 
consequences. We previously found that a single injec-
tion of TNF- α sensitized mice to the behavioural and 
hormonal consequences of later exposure to a bovine 
serum albumin (BSA) antigen 3–4 weeks later [23, 24].
Methods
Animals
Female and male C57BL/6 mice were purchased from 
Charles River Laboratories at 6–8  weeks of age. At the 
time of breeding, female breeders were 17–19 week-old 
second-time breeders, and males were first-time breed-
ers 6–8  weeks old. Male mice were bred in-house and 
only male offspring were used in all experiments. Mice 
were housed in a standard housing environment on a 
12-h light–dark cycle and received water and peanut-free 
Harlan Laboratories 2014 Rodent Chow food ad  libi-
tum for the duration of the experiment. All experiments 
were approved by the Carleton University Animal Care 
Committee.
Crude peanut extract
Crude peanut extract (CPE) for the intradermal challenge 
was isolated from partially defatted peanut flour (12% 
fat, light roast) generously donated by the Golden Peanut 
Company (Alpharetta, GA). Briefly, a 1:8 (w:v) solution 
of peanut flour and 1 M NaCl adjusted to pH 9.5 using 
NaOH was mixed at room temperature for half an hour 
and then centrifuged at 4  °C and 5000×g for 25  min to 
obtain the supernatant. The supernatant was collected 
and the pH was adjusted to 4.0 before being centrifuged 
at 4  °C for 50  min at 1000×g. Finally, the protein iso-
late was obtained by washing the precipitate with water 
adjusted to pH 4.0. The CPE used for the intradermal 
challenges was made up as a 10 µg/µL solution in distilled 
water.
Antibiotic treatment
Beginning on the day of parturition, six dams and their 
pups received a clinically relevant dose [19, 25] of van-
comycin (Sigma-Aldrich), an antibiotic that targets 
gram-positive bacteria, through their drinking water 
(100  mg/L) for 3  weeks. Antibiotic water was changed 
every 3  days and phosphate buffer solution (PBS) was 
added to the water (0.5 mM) to facilitate vancomycin dis-
solution as per the instructions of the manufacturer. At 
3 weeks of age (Day 22), pups were weaned and remained 
housed with their littermates while continuing to receive 
vancomycin in their drinking water (100  mg/L) until 
they were 6 weeks old (Day 42). The remaining dams and 
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pups received normal drinking water with PBS (0.5 mM) 
as a control over the same time period. After Day 42, all 
pups received normal tap water for the remainder of the 
experiment.
Murine model of peanut allergy
Sensitization phase
At 6 weeks of age and following the antibiotic treatment 
(Day 43), mice were weaned and placed into individual 
housing. One-third of the pups in each antibiotic/con-
trol treatment condition (i.e. 7–9 mice/group) were orally 
exposed to peanut antigen and TNF-α (TNF-α + PB-
sensitized group). Specifically, these mice received 10 mg 
of peanut butter (equivalent to 2.7  mg peanut protein; 
Kraft All Natural peanut butter) in 100 µL distilled water 
spread onto 0.5  g of a digestive cookie (Mr. Christie’s 
 Arrowroot® cookies). In a pilot study (unpublished data), 
we found that 2 µg of TNF-α acts as an effective adjuvant 
to elicit an allergic reaction (ear swelling) upon subse-
quent exposure to the peanut protein antigen through 
an ear punch coated in CPE or peanut butter oil. Hence, 
TNF-α was given together with the peanut protein as an 
adjuvant to boost the immune response to the peanut 
antigen. Another one-third of the mice in each antibiotic/
control condition were exposed to 2 µg of TNF-α alone 
(TNF-α group). The remaining third of the mice (con-
trol group)_ received 100 µL of distilled water alone on a 
digestive cookie.
Challenge phase
Two weeks after the sensitization treatment (Day 57), 
all mice were challenged intra-dermally with an ear 
punch. The intra-dermal ear punch challenge consisted 
of punching the left ear pinna of each mouse with an ear 
punch coated in a solution of 10 µg/mL CPE in distilled 
water. The right ear pinna was punched with a separate 
ear punch coated in distilled water as a control. Each 
ear punch was washed with ethanol between animals. 
One hour following the ear punch, all mice received 
an intraperitoneal (IP) injection of 5  mg of peanut but-
ter dissolved in 100 µL of saline. We thus assessed both 
locally (ear) and systemically induced (IP) allergic reac-
tions. It should be noted that IP administration is a non-
physiological route of antigen delivery. Yet, this route of 
systemic challenge was chosen to avoid the stresses of 
oral gavage, as stress responses can significantly impact 
immune responses. One hour following the IP injection 
all animals were sacrificed via rapid decapitation with 
surgical scissors. Figure 1 shows the complete timeline of 
the experimental set-up.
Allergic outcomes
Ear punch swelling response
At 15-min intervals for 30  min following the ear punch 
challenge, both the left and the right ears were scored on 
a scale of 0–3 for signs of swelling and irritation indica-
tive of allergy. On this scale, 0 indicated no swelling, red-
ness, or signs of irritation or scratching; 1 indicated an 
enlarged ear punch hole; 2 indicated mild swelling of the 
ear, and swelling at the base of the ear; and 3 indicated 
an enlarged ear, swelling at the base of the ear causing 
the ear to protrude from the head, mild redness, and/
or bleeding from the ear area (Table  1). Ear sensitivity 
responses were calculated by subtracting the total irri-
tation score over the 1-h period for the right ear from 
the total ear irritation score for the left ear. So, [Left: 
Experimental Ear (treated with peanut antigen)] − [Right: 
Control Ear (treated with vehicle)] = Ear swelling rating 
(corrected for non-specific swelling from punch pro-
cedure). Then, total ear swelling scores were obtained 
by summing the scores obtained for both 15-min time 
points assessed.
Scratching and allergy/sickness responses
At the 15-min time point following the intra-dermal 
peanut antigen challenge, mice were observed for 2 min 
and assessed for scratching behaviour on a 3-point scale, 
with 0 indicating no scratching over the 2-min interval; 
Fig. 1 Newborn male mice reared on vancomycin or tap water from birth until 42 days of age were sensitized with TNF-α alone, TNF-α and peanut 
butter (PB) together or distilled water  (H2O) on Day 43. On Day 57, all mice were challenged with an ear punch coated in crude peanut extract (CPE) 
and scored for subsequent ear swelling and scratching reactions. One hour later, all mice were challenged with an injection of PB and scored for 
signs of allergy/scratching over 1 h, after which time all mice were sacrificed. Fecal samples were taken from mice throughout the study period and 
analyzed for their microbial contents using Illumina sequencing
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1 indicating moderate scratching over the 5-min inter-
val (defined as 1–5 times over the 2-min interval); and 2 
indicating severe or frequent scratching (defined as > 5 
times over the 2-min interval) (Table 1).
Following the IP peanut butter challenge, mice were 
observed for 60  min for signs of allergy. Scratching 
behaviour was assessed at the 15, 30, 45, and 60-min time 
points following the IP challenge and rated on a 3-point 
scale, with 0 indicating no scratching over the 1  min 
interval; 1 indicating moderate scratching (defined as 
1–2 times over the 1 min interval); and a rating of 2 used 
to indicate severe or frequent scratching (defined as > 2 
times over the 1 min interval). Mice were also rated on 
sickness behaviour at these same time points using our 
well validated scale [24], with a score of 1 indicating nor-
mal looking; 2 indicating slight lethargy, ptosis (droopy 
eyes) or piloerection (puffy fur); 3 indicating very lethar-
gic, ptosis and piloerection, curled body posture; and 4 
indicating a very sick appearance, ptosis, piloerection, 
curled body posture, difficulty breathing, and general 
non-responsiveness. Total scores were obtained by sum-
ming the scores assigned at each time point assessed.
IgE measurements
Immediately following the 1-h observation period 
after the IP challenge, mice were sacrificed by rapid 
decapitation with surgical scissors and trunk blood was 
collected into chilled EDTA filled (10  µg) tubes for fur-
ther analysis. Whole blood was centrifuged at 3000×g for 
15 min to obtain plasma and stored at − 80 °C. Total cir-
culating IgE levels were determined by sandwich ELISA 
using a commercial mouse IgE ELISA kit after being sent 
to ITR Laboratories Canada Inc (ITR SOP # IMM BIOM 
42.0; available on file at ITR). Briefly, a 96-well plate was 
coated with a rat anti-mouse IgE monoclonal antibody. 
Standards and samples were then added to the wells, fol-
lowed by a biotinylated rat monoclonal anti-mouse IgE 
detection antibody cocktail. These antibodies were sub-
sequently detected by adding avidin-horseradish peroxi-
dase followed by TMB Substrate Solution and absorbance 
was read at 450  nm with a microplate reader. The data 
was acquired using the Biotek Powerwave XS microplate 
reader coupled to Biotek Gen5 Secure software for data 
analysis and curve fit purposes.
Microbial analysis
Fecal samples were taken from each of 12 cages of ani-
mals on Days 21, 28, 35, and 42 and stored at − 80 °C in 
a 1:1 glycerol: water solution until needed. Samples were 
sent on dry ice to Microbiome Insights Inc., Vancouver 
to be subsequently analyzed for their microbial content. 
Briefly, DNA was extracted from fecal samples using the 
Table 1 Score, symptoms, and images for ear swelling responses observed over 1 h following an ear punch challenge
The two extremes (scores of 0 and 3) are shown for comparison
Score Symptoms Image
0 No signs of ear swelling (arrow), redness, or irritation
3 Enlarged ear (arrow), swelling at the base of the ear caus-
ing the ear to protrude from the head, mild redness, 
and un-kept fur on the affected side of the body, and/or 
bleeding from the ear area
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Qiagen QIAamp DNA Stool Mini Kit and prepared for 
sequencing on a MiSeq machine using primers targeting 
the V3 region of the 16S rRNA gene and according to the 
Schloss lab protocol “16S Sequencing with the Illumina 
MiSeq Personal Sequencer” Standard Operating Pro-
cedure v3.1 (March 18, 2014) by Kozich et al. [25], with 
minor modifications. Sequences were then bioinformati-
cally processed and analyzed following the MiSeq SOP 
wiki for the mothur v.1.34.4 software to determine the 
diversity and composition of the microbial contents of 
the samples.
Statistics
All statistics were done using SPSS Version 20. Results 
were analysed using a 2 (early life treatment: antibiotic 
vs vehicle) × 3 (sensitization treatment: Vehicle, TNF-α, 
TNF-α + PB) factorial ANOVA followed by Fischer’s least 
significant difference (LSD) post hoc tests. For significant 
interactions, LSD tests were used to compare means of 
the effects comprising these interactions. When litter 
was included as a covariate in the analysis (ANCOVA) on 
the basis of finding significant differences in microbiome 
composition among litters, this did not alter findings that 
were significant and thus only results from the simple 
ANOVA are reported.
Results
Ear swelling scores
Total ear swelling responses following the ear punch 
challenge were significantly higher among antibiotic-
treated animals as compared to the control animals 
 (F1,38 = 13.356; p < 0.05; Fig.  2). Moreover, the sensitiza-
tion treatment had a significant effect on ear swelling 
responses  (F2,38 = 5.062, p < 0.05), and the interaction 
term between antibiotic treatments and sensitization 
treatment was significant  (F2,38 = 6.807, p < 0.05; Fig.  2). 
Mean comparisons between individual groups showed 
that antibiotic-treated mice sensitized with TNF-α + PB 
treatment had significantly higher total ear scores as 
compared to all other groups (Fig.  2). Additionally, 
among mice sensitized with TNF-α alone, those previ-
ously exposed to vancomycin had significantly higher 
ear swelling score than those not exposed to vancomycin 
(p < 0.05, Fig. 2).
Ear scratching scores
Antibiotic and control mice differed significantly in 
scratching behaviour  (F1,38 = 6.098, p < 0.05), with post 
hoc LSD tests showing antibiotic-treated mice scratch-
ing more than control mice. There was also a significant 
interaction between antibiotic and sensitization treat-
ments  (F2,38 = 4.220, p < 0.05). Pairwise comparisons of 
Fig. 2 Mean total ear swelling scores of mice treated for the first 6 weeks of life with the antibiotic (AB) vancomycin are shown on the right and 
those that only received tap water during this time (control) are shown on the left. Following this treatment, animals were later exposed to distilled 
water (H2O), TNF-α, or TNF-α and peanut butter (TNF-α + PB) on Day 43. After a further 2 weeks, all mice received an ear punch challenge to the 
left ear with crude peanut extract in distilled water on Day 57. Ear swelling responses were scored on a scale of 0–3, with 3 being the most severe 
swelling response, at the 15- and 30-min time points following the ear punch challenge and were corrected for swelling responses observed in the 
right ear following an ear punch with distilled water received at the same time. *p < 0.05 by 2 × 3 ANOVA and Fischer’s least significant difference 
post hoc tests. Error bars represent one standard error
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individual means showed that scratching scores were sig-
nificantly higher among vancomycin-treated mice sensi-
tized with TNF-α + PB compared to those that received 
vehicle sensitization or that did not receive the antibiotic 
pre-treatment (Fig. 3).
Allergy scores
Allergy scores did not significantly differ among 
the treatment groups. However, animals exposed to 
antibiotic and sensitized with TNF-a + peanut antigen 
appeared to exhibit slightly higher allergy scores (at 15, 
30 and 45 min) than control animals (Fig. 4). However, 
there was substantial variability in the data, such that 
it appeared that there were separate populations of 
“responder” and “non-responder” mice and exceedingly 
large sample sizes would be required to complete any 
further analyses of such sub-groups.
Fig. 3 Interaction plot of mean scratching scores of mice reared for 6 weeks on the antibiotic (AB) vancomycin or on tap water (control) and 
then treated with either distilled water  (H2O), TNF-α, or TNF-α and peanut butter (TNF-α + PB) (n = 6–9/group). Two week later mice were then 
challenged with the peanut antigen. Scratching behaviour was observed for 60 s 15 min following the ear punch challenge on a scale of 0–2, with 
3 being the most severe scratching response. *p < 0.05 by 2 × 3 ANOVA and Fischer’s least significant difference post hoc tests. Antibiotic treatment 
significantly affected ear-scratching responses and showed a significant interaction with sensitization treatment effects (p < 0.05)
a b
Fig. 4 Mean allergy scores of mice reared for 6 weeks on the antibiotic vancomycin (AB) or on tap water (control) and sensitized to distilled water 
(H2O), TNF-α, or TNF-α and peanut butter on Day 43 at a 15 min and b 45 min on Day 57. Allergy scores out of 5 were determined at each time 
point based on the presence/severity of anaphylactic allergy symptoms, with a score of 5 being the most severe. Clearly, no animals approached 
anything near an anaphylactic reaction
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Sickness scores
No significant differences in overall sickness scores were 
observed among treatment groups at any time point fol-
lowing the IP peanut butter challenge (data not shown). 
Sickness ratings were generally quite low in all mice, with 
no animal scoring above a 2 (modest sickness symptoms) 
at any time point. Thus, there was no indication of an 
anaphylactic-like response following antigen challenge 
using our present experimental allergy model.
Total plasma IgE levels
Paralleling the allergy scores, circulating IgE levels var-
ied among treatment conditions but were quite variable. 
Indeed, although the initial ANOVA comparing treat-
ment groups was not significant (p = 0.20), we conducted 
follow up comparisons based on our a priori hypothesis. 
These comparisons revealed that antibiotic pre-treated 
mice later exposed to the TNF-α + peanut antigen treat-
ment had significantly elevated IgE levels compared to 
non-antibiotic vehicle treated control animals (p < 0.05). 
However, these antibiotic-treated mice did not differ 
from their non-antibiotic treated counterparts that were 
also sensitized with the PB + TNF-α treatment (Fig. 5).
Microbial species
The microbial species present in the feces of antibiotic-
treated and control mice differed dramatically with 
respect to several parameters (Fig.  6). Concomitant 
with an observed reduction in Firmicutes, Proteobacte-
ria were markedly increased in relative abundance in the 
fecal samples of antibiotic-treated mice as compared to 
non-antibiotic treated mice (p < 0.05, Fig. 7). Additionally, 
the microbial profiles of the gut microbiota in antibiotic-
treated mice exhibited greater inter-individual variability 
as compared to those in the non-antibiotic treated mice 
(Fig.  7). Litter was also found to influence the microbi-
ome profile among antibiotic-treated mice, with the A1 
litter displaying the most distinct microbial commu-
nity profile as compared to animals born to dams A2–6 
(Figs. 6 and 7). Importantly, in contrast to samples taken 
from non-antibiotic treated mice, the bacterial com-
munity composition of the fecal samples from antibi-
otic-treated mice showed significant changes over time 
(permutational analysis of variance; p < 0.05), suggesting 
a more reactive microbial environment.
Discussion
Recent research in humans and rodents has suggested 
possible links between antibiotic use and the develop-
ment of food, respiratory or skin allergies [2, 19, 26, 27]. 
Given that the gut microbiota is known to interact with 
the immune system to modulate immune cell matura-
tion [28] and polarization, alterations in the early life gut 
microbiota may have an immunomodulatory influence 
on immune cells and responses involved in determining 
peanut allergy susceptibility [2, 29]. Several epidemio-
logical studies have found associations between altered 
early life gut microbiota communities and an increased 
likelihood of later developing allergic diseases [30–36]. 
Moreover, advances are being made in understand-
ing the mechanisms through which the microbiota and 
their microbial products alter immune cell functioning 
[29, 37–39]. Our present data does suggest that perina-
tal antibiotic alters the microbial species. This was corre-
lated with an enhanced sensitivity to certain (ear swelling 
and scratching) but not other (systemic allergic and sick-
ness scores) outcomes in response to later exposure to 
peanut antigen and the cytokine, TNF-α, In addition to 
having potential clinical relevance with regards to food 
allergies, these data highlight interesting interactions 
between immunogenic stressors over time.
Exposing newborn mice to vancomycin has been 
shown to have a substantive effect on the gut microbiota 
of these mice, altering the composition of the micro-
bial community much more dramatically than adult 
exposure to vancomycin. Accordingly, we found that 
vancomycin exposure during the first 6  weeks of life 
dramatically altered the community profile of the gut 
microbiota of mice at the phylum level. The gut micro-
biota of antibiotic-treated neonatal mice had reduced 
levels of Firmicutes and Bacteroidetes and higher levels 
of Proteobacteria as compared to control mice. Impor-
tantly, a similar shift in preponderance of Proteobacteria 
is known to be associated with increased inflammation 
Fig. 5 Mean circulating IgE levels in vehicle (Veh) treated controls, 
as well as in mice reared for 6 weeks on the antibiotic vancomycin 
(AB). Priming with TNF-α and peanut butter (PB) on Day 43 followed 
by later challenge PB again on Day 57 increased IgE levels. However, 
the rise only reached significance in those animals that had been 
pre-treated with the antibiotic, relative to controls (p < 0.05)
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[40]. As Gram negative organisms, Proteobacteria con-
tain large amounts of lipopolysaccharide (LPS) molecules 
within their outer membranes, which are among the 
most potent inflammatory inducers. Furthermore, Pro-
teobacteria have been associated in other studies with 
numerous inflammatory conditions, including asthma 
and atopy [41].
Several murine models of peanut allergy have emerged 
in recent years [21]. These models differ in their use of 
mouse strain, route of antigen/adjuvant administration 
(oral gavage, IP, epicutaneous), use of adjuvants, num-
ber of sensitization injections, doses of antigen used, and 
allergic outcomes assessed [42–47]. Many peanut allergy 
models use oral gavage to administer the peanut antigen 
and use cholera toxin as an adjuvant to sensitize mice 
and favour allergic-like Th2 responses [21, 22]. How-
ever, these methods are hampered by the fact that the 
cholera toxin adjuvant has numerous toxic effects and 
artificially induces an immune reaction that may not be 
representative of how peanut allergies naturally occur 
[21]. Additionally, the gavage route of administration is 
very stressful for the animal and induces marked stress 
hormonal responses [48]. Thus, we sought to utilize the 
naturally occurring pro-inflammatory cytokine, TNF-
α, as an adjuvant “immune sensitizer” and avoided the 
overly stressful gavage in favor of voluntary oral and IP 
routes of administration.
TNF-α has previously been found to act as an adju-
vant capable of augmenting the inflammatory effects 
of the BSA and house dust antigens [23, 49]. Impor-
tantly, TNF-α is endogenously released from mast cell 
preformed granules upon antigen re-exposure during 
allergic reactions, thereby contributing to the recruit-
ment of phagocytic and effector immune cells [50, 51]. 
This may in part explain why TNF-α priming alone (i.e. 
in the absence of concurrent peanut antigen exposure) 
elicited some degree of ear swelling in response to the 
antigen challenge. However, it is important to note that 
such a response was only evident in mice that previ-
ously received the early life antibiotic exposure (Fig.  2), 
suggesting that TNF-α may either act as an adjuvant/
immune sensitizer only within a particular antibiotic-
disrupted gut microbiota environment. It is possible that 
endogenously derived TNF-α plays a role in the devel-
opment of allergies through inflammatory processes at 
the epithelial barrier of the gut. Thus, a murine model 
of peanut allergy employing this protein as an adjuvant 
may represent a more clinically relevant model that more 
accurately recapitulates certain elements of the induc-
tion phase of human peanut allergies. Indeed, our data 
Fig. 6 Distribution of phylum-level bacterial taxa present in the fecal samples of mice from 12 different litters reared from parturition (Day 1) 
for 6 weeks on the antibiotic vancomycin (AB; left side of figure) or on tap water (dH2O; right side of figure). The figure is based on operational 
taxonomic unit abundances aggregated into phyla. Other in the figure legend represents unclassified phyla and Acidobacteria. Litters of mice from 
6 different mothers reared on antibiotics (A1-6-x) and from 6 mothers reared on regular water (C1-6-x) until weaning. Mice were housed with their 
mothers until weaning at Day 22 and subsequently housed with their littermates while continuing to receive either vancomycin or regular water 
until Day 43. Analyzed samples were taken from cages containing a single mother and all of her pups on Days 21 (A/CX-6), 28 (A/CX-7), 35 (A/CX-8) 
and 42 (A/CX-9)
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suggest that when administered concurrently with pea-
nut butter during the sensitization phase, TNF-α acts as 
an effective adjuvant.
The localized (ear swelling and itching) allergic phe-
notypes observed in the present study may have been 
due to increased baseline inflammatory tone (owing 
to an elevation of Proteobacteria) or alternatively to a 
loss of Clostridia bacteria in the gut of the antibiotic-
treated mice. Indeed, Clostridiales are among the 
bacterial orders within the Firmicutes phylum often 
most affected by vancomycin treatment [52], and they 
may play a central role in protecting against allergic 
immune responses under normal conditions [18, 52]. 
For instance, Stefka et  al. [18] previously showed that 
Clostridia found in the commensal flora play a central 
role in protecting against peanut allergies by increas-
ing IgA secretion and inducing intestinal epithelial cell 
and T cell IL-12 secretion to improve the integrity of 
the intestinal membrane barrier and reduce its perme-
ability to antigens [18]. Moreover, these bacteria can 
interact with the host to promote the development of 
intestinal Tregs, which contribute to an anti-inflamma-
tory environment within the gut, [53] and influence the 
profile of the gut microbiota by inducing the expression 
of the intestinal antimicrobial peptide, REG3β [18]. 
It is important to note, however, that the association 
illustrated in our study does not imply causation and 
we can only speculate as to possible links between the 
observed symptoms and the gut microbiota changes. 
Also, we fully acknowledge that our measures of aller-
gic outcome are somewhat subjective. That said, all 
measures of swelling and scratching were rigorously 
calculated by well-trained experimenters blind to the 
treatment groups.
Fig. 7 Each data point is a specific litter sampled and the different shapes represent the different sampling times. Multidimensional scaling of 
pair-wise Bray–Curtis distances among microbial community profiles measures how similar or different the microbial communities are, with 
divergence from zero reflecting greater variation as a function of time of sampling and specific litter sampled. Fecal samples taken from mice 
reared from parturition (Day 1) for 6 weeks on the antibiotic vancomycin (AB) or on regular water (dH2O) as controls. Litters were housed with their 
mothers until weaning at Day 22 and subsequently housed with their littermates until Day 43. Samples were taken on Days 21, 28, 35, and 42 from 
cages containing a single mother and all of her pups (Day 21) or from cages containing only pups from the same litter (Days 28, 35, and 42)
Page 10 of 11Boutin et al. Allergy Asthma Clin Immunol  (2018) 14:42 
Conclusions and caveats
Although we raise the possibility of a link between anti-
biotic-induced early life disruption to the gut microbi-
ota and later sensitivity to certain immunogenic effects, 
further studies are required to be able to verify such a 
link and provide mechanistic details as to the nature of 
any such relationship. Furthermore, it should be under-
scored that using different antibiotics might yield dif-
ferent outcomes. Vancomycin is often reserved for 
serious infections and targets gram positive bacteria 
such as Staphylococcus aureus, which can lead to intes-
tinal inflammation. Other broader spectrum antibiotics 
would be expected to differentially affect the gut micro-
biota and hence, potentially impact different allergic 
outcomes. Moreover, having now shown that broad-
spectrum antibiotic exposure induces shifts in the 
microbiota and affects markers of allergy, future work 
should also focus on using more narrow-spectrum anti-
biotics to determine the relative importance of specific 
populations of bacteria in mediating these immunolog-
ical effects. To further show a causal role for antibiotic-
induced microbial shifts in mediating peanut allergy, 
fecal transplant experiments aimed at determining the 
ability of microbial restoration to rescue allergic pheno-
types could be useful [54, 55].
The lack of obvious sickness symptoms observed 
following the peanut protein challenge as would be 
expected with a systemic or anaphylactic reaction 
may be related to findings of only elevated circulat-
ing IgE levels in sensitized and antibiotic-treated mice. 
Of course, an important caveat of our study is that we 
assessed total and not peanut-specific IgE. At the time 
of this study, we did not have access to this assay and we 
presently have no biological samples remaining. Thus, 
we may have missed peanut-specific antibody changes.
Taken together, our findings provide evidence of the 
utility of TNF-α as an adjuvant in a murine model of 
peanut allergy and are consistent with the hypothesis 
that early life exposure to antibiotics alters microbial 
colonization of the intestinal tract [39] and this was 
associated with ear swelling and scratching follow-
ing later intra-dermal peanut antigen challenge. The 
highly coordinated and intricate relationship that exists 
between the gut microbiota and host immunity has 
resulted from millions of years of past evolutionary his-
tory; suggesting that some modern lifestyle practices 
may be disrupting such precisely defined interactions.
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